Moderna's messenger RNA (mRNA)-1273 is one of the leading COVID-19 vaccine candidates. Another COVID-19 vaccine developer, Pfizer, last week reported 90% efficacy for its candidate, BNT162b2.

Moderna's Coronavirus Efficacy (COVE) study has enrolled over 30,000 participants in the U.S. and is being conducted in collaboration with the U.S. National Institutes of Health Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research Development Authority (BARDA).

In the study, 15,000 people received the mRNA-1273 candidate while 15,000 received a placebo. The primary endpoint of the study was the number of individuals with a confirmed case of COVID-19 two weeks after receiving a second dose of the vaccine.

There were a total of 95 cases of COVID-19 in the interim analysis, with 90 cases occurring in the placebo group versus five cases observed in the mRNA-1273 group, producing an efficacy rate of 94.5%.

The secondary endpoint analyzed in the study was severe cases of COVID-19. There were 11 severe cases, and all occurred in the placebo group. The data monitoring board did not report any significant safety concerns in its review of the phase III COVE study. The board also concluded that the vaccine was generally well-tolerated.

Based on the interim report, Moderna plans on submitting an emergency use authorization with the U.S. Food and Drug Administration in the coming weeks. Moderna also plans on submitting applications for authorizations to other global regulatory agencies.

By the end of 2020, the company expects to have approximately 20 million doses of mRNA-1273 ready to ship in the U.S. and is on track to manufacture 500 million to up to 1 billion doses globally in 2021.

Moderna finalizes interim results for COVID-19 vaccine
Moderna has completed case accrual for its first interim analysis of a phase III study of its COVID-19 vaccine candidate.

Takeda expands COVID-19 vaccine supply with Moderna, Japan
Takeda Pharmaceutical will import and distribute 50 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, starting in...

Moderna gets nod from EMA to submit marketing authorization
Moderna has received written confirmation from the European Medicines Agency (EMA) that messenger RNA (mRNA)-1273, the company's COVID-19 vaccine candidate,...

Moderna secures $56M for mobile vaccine manufacturing
Moderna has received $56 million from the Defense Advanced Research Projects Agency to fund manufacturing of nucleic acid vaccines and therapeutics.

Moderna touts positive vaccine results in older populations
Results from Moderna's phase I clinical trial indicated that its candidate for a COVID-19 vaccine, messenger RNA (mRNA)-1273, is well-tolerated and generates...

Canada orders 20M doses of Moderna COVID-19 vaccine
The Canadian government increased its confirmed order commitment to 20 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate.

Moderna to potentially supply Japan with 40M doses of COVID-19 vaccine
Moderna is in discussion with the Ministry of Health, Labour, and Welfare of Japan to potentially purchase 40 million or more doses of its messenger...